VI-0521
AssetSmall molecule
Fixed-dose combination product containing metformin for obesity and metabolic regulation
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- AMPK signalling
- Indications
- 1
- Trials
- 1,347
- Developers
- 1
Indications
1Obesity
Phase 1COMPLETEDNCT00842400clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners1
- Trials1,347
- Evidence for its targets3
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 3 sources